27/04/2026 – AB Science announces today that a final agreement has been reached with its financial creditors for the 24-month deferral of repayment of its bank debt and the 12-month deferral of repayment of a loan subscribed with the EIB Download PDF Post navigationPreviousPrevious post:New publication on medrxiv demonstrating substantial survival benefits and preserved quality of life with masitinib in ALS patientsNextNext post:AB Science announces the successful completion of a EUR 3.2 million private placementRelated PostsStonegate Capital Partners updates its coverage of AB Science’s stock with a target price of EUR 4.25 per share2 June 2026AB Science announces that its stock continues to be covered by Maxim Group, with a target price of €4.00 per share25 May 2026Annual financial results as of 31 December, 202513 May 2026AB Science announces the successful completion of a EUR 3.2 million private placement29 April 2026New publication on medrxiv demonstrating substantial survival benefits and preserved quality of life with masitinib in ALS patients20 April 2026Update on clinical development program16 April 2026
Stonegate Capital Partners updates its coverage of AB Science’s stock with a target price of EUR 4.25 per share2 June 2026
AB Science announces that its stock continues to be covered by Maxim Group, with a target price of €4.00 per share25 May 2026
New publication on medrxiv demonstrating substantial survival benefits and preserved quality of life with masitinib in ALS patients20 April 2026
